Targeted Radionuclide Therapy with A (177)Lu-labeled Anti-HER2 Nanobody

RIT has become an attractive strategy in cancer treatment, but still faces important drawbacks due to poor tumor penetration and undesirable pharmacokinetics of the targeting vehicles. Smaller radiolabeled antibody fragments and peptides feature highly specific target accumulation, resulting in low...

Descripción completa

Detalles Bibliográficos
Autores principales: D'Huyvetter, Matthias, Vincke, Cécile, Xavier, Catarina, Aerts, An, Impens, Nathalie, Baatout, Sarah, De Raeve, Hendrik, Muyldermans, Serge, Caveliers, Vicky, Devoogdt, Nick, Lahoutte, Tony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4038753/
https://www.ncbi.nlm.nih.gov/pubmed/24883121
http://dx.doi.org/10.7150/thno.8156

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4038753/
https://www.ncbi.nlm.nih.gov/pubmed/24883121
http://dx.doi.org/10.7150/thno.8156

Ejemplares similares